QIMR Berghofer researchers have discovered a potential new cancer immunotherapy target that involves switching off a regulatory cell to stop tumours growing and spreading.
The study findings have been published today in Cancer Discovery, a journal of the American Association for Cancer Research.
Senior researcher and head of QIMR Berghofer’s Cancer Immunoregulation and Immunotherapy Laboratory, Associate Professor Michele Teng, said in future the discovery could potentially help treat patients with cancers where other current immunotherapies have not worked.
“Our work on mice shows for the first time that many tumours display the molecule MR1 on their cell surface, and when it’s present, this molecule turns on an important regulatory cell that prevents the body’s own immune system from fighting the cancer,” Associate Professor Teng said.
“We found if a type of regulatory cell called MAIT (mucosal-associated invariant T) cells are turned on, they stop immune or white blood cells known as T and NK cells from attacking and killing off tumour cells.
“The cancer is effectively creating its own defence mechanism to evade immune attack and survive. The display of MR1 activates the MAIT cells, which in turn switch off cancer-fighting T and NK cells.
“While other regulatory cells of the immune system are known to stop T and NK cells from killing tumour cells, this is the first time it’s been shown that these regulatory MAIT cells can do this job.”
Associate Professor Teng said her team found that by giving mice an antibody that blocked MR1, this stopped the MAIT cells from becoming activated, and the T and NK cells could respond, slowing cancer growth and stopping it spreading.
“This work demonstrates that antibodies that block MR1 could in future be an effective new immunotherapy,” Associate Professor Teng said.
“It probably won’t work on every cancer, but it looks like it could be effective in treating cancers that can display the MR1 molecule. It also means this display of MR1 could be used to screen which patients would respond to this immunotherapy.
“We now need to replicate this research in humans.”
Associate Professor Teng said while the research was at a very early stage and required more work, it was promising.
“The next step is to try to understand what kind of human tumours display MR1 as a protective mechanism, which would then help us identify which tumours would respond best to MR1-blocking immunotherapy,” she said.
“Immunotherapies have been effectively used to treat more than 15 different cancer types but the proportion of patients that respond for each cancer can differ.
“In patients with advanced melanoma for example, current approved immunotherapies work in about 50 per cent of cases, but half do not respond, and that’s why we need to find new therapies.”
Learn more: POTENTIAL NEW CANCER TREATMENT A STEP CLOSER
Go deeper with Bing News on:
Cancer immunotherapy
- New gene signature could transform immunotherapy for gastrointestinal cancers
Despite significant progress in treating gastrointestinal (GI) cancers through surgical resection, chemotherapy, radiotherapy, and targeted therapy, the objective response rate (ORR) for immune ...
- Unlocking the immune system: cGAS-STING pathway offers new hope for cancer treatment
Cancer immunotherapy, which leverages the body's immune system to target tumors, has emerged as a pivotal strategy in oncology. This paradigm shift from conventional treatments offers a more precise ...
- Breaking: AI Could Transform Cancer Treatment by Predicting Immunotherapy Success
In this article, we’ll explore a breakthrough development in the fight against cancer: how artificial intelligence (AI) is poised to predict immunotherapy success. This has the potential to ...
- Unlocking the immune system: cGAS-STING pathway offers new hope for cancer breakthroughs
A groundbreaking study has recognized the cGAS-STING signaling pathway as a formidable ally in the immune system's battle against cancer. This ...
- Is there a cost to convenience? Canada approves new cancer immunotherapy treatment
Atezolizumab is currently used in intravenous form as Tecentriq IV to treat various tumours. The new subcutaneous type of cancer immunotherapy treatment injects the drug under the skin instead of ...
Go deeper with Google Headlines on:
Cancer immunotherapy
[google_news title=”” keyword=”cancer immunotherapy” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Blocking immunotherapy
- Experimental Blood Thinner Can Be Reversed With Fast-Acting Antidote
Researchers developed an experimental anticoagulant, or blood thinner, that blocks the activity of a protein involved in the formation of blood clots. The drug’s action can be rapidly reversed with an ...
- Headline: UK cancer patient pioneers groundbreaking skin cancer vaccine trial
A novel immunotherapy trial, using mRNA technology like in COVID vaccines, aims to prevent skin cancer recurrence. The trial combines a personalized mRNA vaccine with Keytruda, blocking an immune ...
- Improving cancer immunotherapy by prolonging T-cell survival
In the past decade, immunotherapy has emerged as the fourth pillar of cancer treatment, joining surgery, radiotherapy and chemotherapy. It is an approved treatment for 15 cancers, including melanoma ...
- Engineered peptides show promise in cancer immunotherapy
In a new study published today in Nature Biomedical Engineering, researchers at The University of Texas MD Anderson Cancer Center have designed a new method for developing immunotherapy drugs using ...
- Has Immunotherapy Found Its Place in Pancreatic Cancer?
A new study suggested that adding nivolumab to neoadjuvant treatment improves outcomes in patients with borderline resectable pancreatic cancer.
Go deeper with Google Headlines on:
Blocking immunotherapy
[google_news title=”” keyword=”blocking immunotherapy” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]